Eledon Pharmaceuticals, Inc. (ELDN)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.300.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Eledon Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.166
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-0.95
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-0.83

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advancement of drug candidates in autoimmune and ALS trials	Eledon is a clinical-stage biotech focused on autoimmune and ALS drugs.	Intact	Trial failures or halted studies	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS loss narrows toward zero	A primary condition in Eledon Pharmaceuticals, Inc.'s published investment case. The stated target is EPS loss improves from -0.87 in FY26 to better than -0.72 in FY27.	Broken	EPS loss worsens or stays below -0.87 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Cash funds operations into 2Q 2027	It has cash to fund operations into 2Q 2027.	Intact	Cash runs out before 2Q 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 0
2026-07-25	Unavailable	Unavailable	2 / 0
2026-07-26	Unavailable	Unavailable	2 / 0
2026-07-27	Unavailable	Unavailable	2 / 0
2026-07-28	Unavailable	Unavailable	2 / 0
2026-07-29	Unavailable	Unavailable	2 / 0
2026-07-30	Unavailable	Unavailable	3 / 4
2026-07-31	Unavailable	Unavailable	3 / 4
2026-08-01	Unavailable	Unavailable	2 / 0
2026-08-02	Unavailable	Unavailable	3 / 4
2026-08-03	Unavailable	Unavailable	2 / 0
2026-08-04	Unavailable	Unavailable	2 / 0
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	2 / 0
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	Unavailable	2 / 0
2026-08-11	Unavailable	Unavailable	2 / 0
2026-08-12	Unavailable	Unavailable	3 / 4
2026-08-13	Unavailable	Unavailable	2 / 0
2026-08-14	Unavailable	Unavailable	2 / 0
2026-08-15	Unavailable	Unavailable	2 / 0
2026-08-16	Unavailable	Unavailable	2 / 0
2026-08-17	Unavailable	Unavailable	2 / 0
2026-08-18	Unavailable	Unavailable	2 / 0
2026-08-19	Unavailable	Unavailable	2 / 0
2026-08-20	Unavailable	Unavailable	2 / 0
2026-08-21	Unavailable	Unavailable	2 / 0
2026-08-22	Unavailable	Unavailable	2 / 0
2026-08-23	Unavailable	Unavailable	2 / 0
2026-08-24	Unavailable	Unavailable	2 / 0
2026-08-25	Unavailable	Unavailable	2 / 0
2026-08-26	Unavailable	Unavailable	2 / 0
2026-08-27	Unavailable	Unavailable	2 / 0
2026-08-28	Unavailable	Unavailable	2 / 0
2026-08-29	Unavailable	Unavailable	2 / 0
2026-08-30	Unavailable	Unavailable	2 / 0
2026-08-31	Unavailable	Unavailable	2 / 0
2026-09-01	Unavailable	Unavailable	2 / 0
2026-09-02	Unavailable	Unavailable	2 / 0
2026-09-03	Unavailable	Unavailable	2 / 0
2026-09-04	Unavailable	Unavailable	2 / 0
2026-09-05	Unavailable	Unavailable	2 / 0
2026-09-06	Unavailable	Unavailable	2 / 0
2026-09-07	Unavailable	Unavailable	2 / 0
2026-09-08	Unavailable	Unavailable	2 / 0
2026-09-09	Unavailable	Unavailable	2 / 0
2026-09-10	Unavailable	Unavailable	2 / 0
2026-09-11	Unavailable	Unavailable	2 / 0
2026-09-12	Unavailable	Unavailable	2 / 0
2026-09-13	Unavailable	Unavailable	2 / 0
2026-09-14	Unavailable	Unavailable	2 / 0
2026-09-15	Unavailable	Unavailable	2 / 0
2026-09-16	Unavailable	Unavailable	2 / 0
2026-09-17	Unavailable	Unavailable	2 / 0
2026-09-18	Unavailable	Unavailable	2 / 0
2026-09-19	Unavailable	Unavailable	2 / 0
2026-09-20	Unavailable	Unavailable	2 / 0
2026-09-21	Unavailable	Unavailable	2 / 0
2026-09-22	Unavailable	Unavailable	2 / 0
2026-09-23	Unavailable	Unavailable	2 / 0
2026-09-24	Unavailable	Unavailable	2 / 0
2026-09-25	Unavailable	Unavailable	2 / 0
2026-09-26	Unavailable	Unavailable	2 / 0
2026-09-27	Unavailable	Unavailable	2 / 0
2026-09-28	Unavailable	Unavailable	2 / 0
2026-09-29	Unavailable	Unavailable	2 / 0
2026-09-30	Unavailable	Unavailable	2 / 0
2026-10-01	Unavailable	Unavailable	2 / 0
2026-10-02	Unavailable	Unavailable	2 / 0
2026-10-03	Unavailable	Unavailable	2 / 0
2026-10-04	Unavailable	Unavailable	2 / 0
2026-10-05	Unavailable	Unavailable	2 / 0
2026-10-06	Unavailable	Unavailable	2 / 0
2026-10-07	Unavailable	Unavailable	2 / 0
2026-10-08	Unavailable	Unavailable	2 / 0
2026-10-09	Unavailable	Unavailable	2 / 0
2026-10-10	Unavailable	Unavailable	2 / 0
2026-10-11	Unavailable	Unavailable	2 / 0
2026-10-12	Unavailable	Unavailable	2 / 0
2026-10-13	Unavailable	Unavailable	2 / 0
2026-10-14	Unavailable	Unavailable	2 / 0
2026-10-15	Unavailable	Unavailable	2 / 0
2026-10-16	Unavailable	Unavailable	2 / 0
2026-10-17	Unavailable	Unavailable	2 / 0
2026-10-18	Unavailable	Unavailable	2 / 0
2026-10-19	Unavailable	Unavailable	2 / 0
2026-10-20	Unavailable	Unavailable	2 / 0
2026-10-21	Unavailable	Unavailable	2 / 0
2026-10-22	Unavailable	Unavailable	2 / 0
2026-10-23	Unavailable	Unavailable	2 / 0
2026-10-24	Unavailable	Unavailable	2 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	6	0	0
2026-07-01	6	0	0
2026-08-01	6	0	0
2026-09-01	6	0	0
2026-10-01	6	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advancement of drug candidates in autoimmune and ALS trialsQualitative condition
EPS loss narrows toward zeroPublished status: Broken
Cash funds operations into 2Q 2027Direct metric needs a verified mapping

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-68.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Eledon Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotech, not an established earnings compounder. The long-term thesis remains in a watch state, with low confidence and high risk.

What's priced into Eledon Pharmaceuticals, Inc.

The evidence snapshot gives no valuation measure or direct account of market expectations, so whether ELDN is cheap or expensive versus peers is unclear. The market appears to be weighing uncertain clinical progress and ongoing cash use, but the evidence does not show how much success is already assumed.

What the fundamentals likely do

Near term, results have been uneven, with an earnings miss in May and an in-line report in August; recent performance remains below the industry cohort. Management says the Phase 3 kidney-transplantation trial is on track to start in late 2026, while cash fell to $88.8 million in the second quarter and is expected to fund operations into the second quarter of 2027.

What Eledon Pharmaceuticals, Inc. hinges on

The multi-year thesis hinges on starting the Phase 3 trial on schedule and showing further progress in islet cell transplantation. Near term, a guidance cut or further weakening in jobs data could add pressure; continued strong results and guidance from sector bellwethers could support sector momentum, but would not resolve ELDN's company-specific risks.